Novo Nordisk Pills Will Control 33% of GLP-1 Market! GLP-1 NEWS скачать в хорошем качестве

Novo Nordisk Pills Will Control 33% of GLP-1 Market! GLP-1 NEWS

The GLP-1 price war is accelerating. Novo Nordisk now says oral GLP-1 pills could capture one-third of the entire market by 2030, and early demand for the new Wegovy tablet shows how many people have been priced out of injections. In this episode of The Downsized News, Christopher and Laraine Durham break down what this shift means for real affordability, access to treatment, and the future of obesity care. The Downsized News – Monday, January 19, 2026 delivers the latest research, policy updates, and industry moves surrounding Zepbound, Mounjaro, Wegovy, and Ozempic, all through the perspective of two people living on GLP-1s every day. Christopher has lost 100 pounds and Laraine 50 pounds using GLP-1 medications, and together they focus on what the headlines actually mean for patients. In Today’s Episode Novo Nordisk: The Pill That Could Capture a Third of the Market – Wegovy tablets launch at $149 as early prescriptions reveal massive demand from people unable to access injections. Novo Nordisk and the Compounding Revolt – Company leaders acknowledge up to 1.5 million Americans may be using compounded GLP-1s because of price barriers. Tom Brady and eMed: GLP-1s Go Mainstream – A new celebrity partnership highlights how quickly obesity treatment is entering popular culture. Eli Lilly & Indiana University: GLP-1s at Work – A five-year study examines productivity, sick days, and employer health costs. Bucks County Robbery: When GLP-1s Become a Target – High prices create a shadow market with real-world consequences. Humana & CenterWell: Insurers Enter the GLP-1 Pipeline – How insurance companies are positioning themselves as gatekeepers. GLP-1s vs Aspirin in Cancer Prevention – New data suggests potential benefits beyond weight and diabetes. Kailera Therapeutics: The Ribupatide Challenge – A new dual-agonist moves into global Phase 3 trials. Wegovy 7.2 mg: Novo Nordisk Raises the Bar – The UK approves a stronger dose and U.S. patients ask when it will arrive. Sponsor This episode is sponsored by Hume Body Pod, an at-home body composition scanner that measures muscle, body fat, visceral fat, and metabolic age in about 60 seconds. Christopher and Laraine found their results to be within 1% of DEXA scans. 👉 Use code DOWNSIZED for exclusive savings Get your Hume BodyPod today and use our exclusive Downsized code for up to 50% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Me Again Iphone GLP-1 App: https://apps.apple.com/us/app/meagain... AMAZON GLP-1 Companion Product Store: https://www.amazon.com/shop/downsized As an Amazon Associate, I earn from qualifying purchases. DOWNSIZED LINKS Website: https://thedownsized.org Be our guest on The Downsized Dish: apply at https://thedownsized.org/downsized-dish/ Https://Thedownsized.Org/ Book The Downsized At Sea Cruise 2026: Https://Thedownsized.Org/Downsized-At... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 GLP-1 Landscape: Market Shifts and Trends 02:11 Novo Nordisk: The Pill That Could Capture a Third of the Market 06:44 Novo Nordisk and the Compounding Revolt 11:26 Tom Brady and eMed: GLP-1s Go Mainstream 13:38 FDA and GLP-1 Safety: The Suicide Risk Review 15:56 Eli Lilly and Indiana University: GLP-1s at Work 18:39 Bucks County GLP-1 Robbery: When GLP-1s Become a Target 21:56 Humana and CenterWell: Insurers Enter the GLP-1 Pipeline 25:08 GLP-1s vs Aspirin in Cancer Prevention 29:11 Kailera Therapeutics: The Ribupatide Challenge 33:23 Wegovy 7.2 mg: Novo Nordisk Raises the Bar